Test Price
2,800 AED✅ Home Collection Available
WISP3 Gene Progressive Pseudorheumatoid Arthropathy of Childhood (PPAC) Genetic Test in UAE
Executive Summary & Core Metrics
The WISP3 gene progressive pseudorheumatoid arthropathy of childhood (PPAC) NGS test uses next‑generation sequencing to analyze the entire coding region of the WISP3 gene. This diagnostic tool confirms autosomal recessive skeletal dysplasia, providing definitive genetic evidence for early intervention, family planning, and specialist‑guided management.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (available daily 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This targeted NGS test delivers deep coverage of the WISP3 gene, offering a faster and more phenotype‑specific alternative to whole‑exome sequencing. The streamlined workflow reduces turnaround time while maintaining high analytical sensitivity for single‑nucleotide variants and small insertions/deletions.
| Feature | WISP3 NGS Test | Whole Exome Sequencing |
|---|---|---|
| Target Precision | Focused WISP3 gene with deep coverage | Broad capture; may miss deep intronic variants |
| Turnaround Time | 3–4 Weeks | Often 6–8 Weeks |
| Clinical Interpretation | Dedicated PPAC phenotype‑specific reporting | Generalized, may require secondary analysis |
Physician Insight & Safety Protocols
“This test must be interpreted in close collaboration with a paediatric rheumatologist and clinical geneticist. A positive result confirms the genetic aetiology but does not predict the exact disease course; a negative result does not exclude the disorder if clinical suspicion remains high. I strongly advise post‑test genetic counselling for all families.”
– Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Advisory & Precautionary Guidance
Important Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Genetic test results do not replace immediate medical advice for acute symptoms.
Exclusion Criteria & Emergency Red Flags
- Minors without documented guardian consent as per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Inadequate or degraded sample (insufficient DNA from blood/FTA card).
- Patients without a valid UAE medical referral for genetic testing.
- ER Red Flags: Acute joint swelling with high fever, sudden loss of motor milestones, or signs of spinal cord compression – seek immediate medical help, do not wait for genetic results.
Patient FAQ & Clinical Guidance
1. What does the WISP3 gene test detect, and who should consider it?
This NGS test identifies disease‑causing variants in the WISP3 gene, confirming progressive pseudorheumatoid arthropathy of childhood in children with suggestive joint stiffness and radiological changes. Any child with early‑onset, non‑inflammatory arthropathy and short stature should be evaluated, alongside family members for carrier status.
2. How is the sample collected, and what is the required pre‑preparation?
A blood sample (or DNA extracted from blood/FTA card) is collected by our VIP mobile phlebotomy team between 8 AM and 11 PM. A detailed genetic counselling session to draw the family pedigree is mandatory before testing; no fasting or medication adjustment is required unless instructed by your physician.
3. How accurate is the result, and what does follow‑up care involve?
Our NGS assay achieves >99.9% analytical sensitivity for single‑nucleotide variants and small indels within the WISP3 gene, with all pathogenic findings confirmed by Sanger sequencing. A positive report should be followed by a multidisciplinary consultation with paediatric rheumatology, orthopaedics, and medical genetics to tailor long‑term surveillance and therapy.
UAE Regulatory & Data Privacy Adherence
ISO 9001:2015 Certified Quality Management (Cert: INT/EGQ/2509DA/3139) – Laboratory operations and home collection adhere to the highest international standards, ensuring reproducibility and patient safety.
All patient data is processed in compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Genetic information is safeguarded with encryption and access controls.
Clinical & Logistical Metadata
| Test Name | WISP3 Gene Progressive Pseudorheumatoid Arthropathy of Childhood (PPAC) NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral blood (EDTA) or FTA card |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | M12.8 |
| LOINC Code | 81267-1 |
| DHA Facility License & Address | License No: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE) |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians